Structure-property relationships in ionically substituted bioactive glasses.

一种哲学：与其试图在体外重建复杂的活组织，不如通过合成材料来提供机械完整性，同时与细胞相互作用，释放身体固有的自我修复能力。Ryerson大学的临床材料组(CMG)在Towler的领导下，正在设计具有离子掺入特性的玻璃基材料，以贯彻这一理念。该计划将建立在托勒实验室现有的已发表(156篇同行评审论文)和专利(总共6篇；相关领域中的2篇)研究的基础上，通过招收学生来实现四个目标：A.高级知识。该计划将扩大对特定离子掺杂剂在离子玻璃和由其制造的胶凝材料的物理、机械和体外生物学性能方面所起作用的基本理解，这些掺杂剂的数量可以量化。该计划将有三个方面：1.合成玻璃和玻璃聚烯烃水泥(GPC)，其配方为足以承受载荷的粘性。2.用溶胶-凝胶电纺法将镓离子掺杂到玻璃中。3.可吸收凝胶渗透剂的研制。B.激励下一代。将为学术、工业和监管行业培训高素质人才(HQP)。他们的技能将通过与Towler在加拿大各地的学术、临床和工业合作者的实习来磨练。确认研发投资的价值。通过该计划取得的进展将导致知识产权用于商业开发。这项工作将使加拿大初创企业、中小型企业(SME)和跨国企业感兴趣。Towler拥有授权技术(Opus-Fil+，DS&D，英国)和衍生技术(新月运营，英国伦敦)。D.提高研究的知名度。Towler将继续在文献中广泛发表，至少保持他现有的速度(每年约15篇论文)，并确保HQP在领先的科学会议上传播他们的工作。在加拿大的头五年(2013-2018年)，托勒从NSERC和CIHR获得了超过260万加元，用于毕业8名博士和4名MASC学生，并指导4名PDF；该组织目前有11名研究生和3名PDF；所有资金都来自联邦拨款，男女比例为50：50。新的HQP将从材料、生物和工程领域招聘；其任务是在对加拿大具有战略意义的领域对他们进行培训。Discovery交付成果可以通过未来的NSERC I2I或协作研究开发(CRD)或NSERC/CIHR协作健康研究项目(CHRP)拨款来开发，并通过后续的认证活动，可以改进整形外科程序，从而缩短住院时间和降低医疗成本。

A philosophy: rather than attempting to recreate the complexity of living tissues ex vivo, synthetic materials can be formulated that offer mechanical integrity whilst interacting with cells to unlock the body's inherent ability to self-repair. The Clinical Materials Group (CMG) at Ryerson University, under the leadership of Towler, is designing glass-based materials with properties tailored by ionic incorporation in order to engage this philosophy. The program will build on existing published (156 peer-reviewed papers) and patented (six in total; two in the relevant space) research in Towler's laboratory by recruiting students to fulfil four objectives: A.Advance knowledge. The program will expand the fundamental understanding of the role that specific ionic dopants, in quantifiable amounts, have on the physical, mechanical and in-vitro biological properties of ionomeric glasses and cementitious materials manufactured from them. The program will have three streams: 1. Synthesis of glasses and glass polyalkenoate cements (GPCs) formulated to be sufficiently viscous for load bearing. 2. Incorporation of Gallium ions into glasses by sol-gel electro-spinning. 3. Development of a resorbable GPC. B.Inspire the next generation. Highly qualified personnel (HQP) will be trained for the academic, industrial and regulatory industries. Their skills will be honed by placements with Towler's academic, clinical and industrial collaborators across Canada. C.Confirm the value of R&D investment. Advancements made through the program will result in IP for commercial exploitation. The work will interest Canadian start-ups, small to medium enterprises (SME) and multinational industry. Towler has both licensed (Opus-Fil+, DS&D, UK) and spun-off (Crescent Ops, London, UK) technology. D.Increase visibility of research. Towler will continue to publish extensively in the literature, at the least maintaining his existing rate (~15 papers, annually) and ensuring HQP disseminate their work at leading scientific conferences. In his first five years in Canada (2013-2018), Towler secured over C$2.6m from NSERC and CIHR to graduate eight PhD and four MASc students and mentor four PDFs; the group currently has 11 graduate students and three PDFs; all funded by federal grants with a 50:50 gender balance between men and women. New HQP will be recruited from the materials, biology and engineering fields; the remit being to train them in areas of strategic interest to Canada.  Discovery deliverables may be exploited through future NSERC I2I or Collaborative Research & Development (CRD) or NSERC/CIHR Collaborative Health Research Project (CHRP) grants and, with follow-on accreditation activities, could improve orthopedic procedures leading to shorter hospital stays and reduced healthcare costs.